🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Immediate Release (IR) Formulation

Found 132 matching trials

A Study to Evaluate the Safety and Efficacy of Three Doses of a Controlled Release Formulation of Varenicline for Smoking Cessation

PHASE2

The purpose of this study is to evaluate the safety, efficacy, and tolerabi...

Status

Withdrawn

Location

Multiple Locations

Start Date

2010-08

Trial ID

NCT00741884

Treatments Being Tested

Varenicline Controlled Release 1.2 mg Varenicline Controlled Release 1.8 mg Varenicline Controlled Release 2.4 mg Varenicline Immediate Release 1 mg Placebo

Study in Advanced Parkinson's Disease Patients With Predictable Motor Fluctuations

PHASE2

The primary objective of this study is to explore the efficacy and tolerabi...

Status

Completed

Location

Multiple Locations

Start Date

2012-01

Trial ID

NCT01515410

Treatments Being Tested

DM-1992 Sinemet IR

Adherence to Stimulant Treatment in Attention-Deficit Hyperactivity Disorder (ADHD) Patients (ASTA)

PHASE4

This study determined to measure non-adherence assessed by the number of no...

Status

Terminated

Location

Universitätsmedizin der Johannes Gutenberg-Universität Mainz - Körperschaft des öffentlichen Rechts

Start Date

2009-03

Trial ID

NCT00852059

Treatments Being Tested

Immediate release methylphenidate (Medikinet®)Extended release methylphenidate (Medikinet retard®)

Evaluation of Immediate Release Tablet

PHASE1

Single dose comparison of liquid and solid formulation, followed by study o...

Status

Completed

Location

Quotient Clinical

Start Date

2016-07

Trial ID

NCT02808741

Treatments Being Tested

F901318 SDD F901318 IR F901318 IR Fasting F901318 IR Fed

A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)

PHASE1

This study will evaluate four different modified release formulation to est...

Status

Completed

Location

Pfizer Investigational Site

Start Date

2009-10

Trial ID

NCT00988624

Treatments Being Tested

Dimebon IR Tablet Dimebon MR1 Dimebon MR2 Dimebon MR3 Dimebon MR4

Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants

PHASE1

The purpose of this study is to gather information about the steady-state p...

Status

Completed

Location

Multiple Locations

Start Date

2014-02

Trial ID

NCT02087579

Treatments Being Tested

Aripiprazole, oral formulation Olanzapine, oral formulation Paliperidone, oral formulation Paliperidone, LAI Quetiapine, oral formulation Risperidone, oral formulation Risperidone, LAI

NanaBis™ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD) Medicine for the Management of Bone Pain From Metastatic Cancers

PHASE3

This is a multi-centre, long term, double blind, clinical protocol for Nana...

Status

Unknown

Location

Multiple Locations

Start Date

2023-11

Trial ID

NCT04808531

Treatments Being Tested

NanaBis™Oxycodone CR Placebo Spray Placebo Tablet Oxycodone IR

Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus.

PHASE1

Study B1621015 will characterize bioavailability, tolerability and pharmaco...

Status

Completed

Location

High Point Clinical Trials Center

Start Date

2014-09

Trial ID

NCT02206607

Treatments Being Tested

PF-04937319 IR MST PF-04937319 MR 1 PF-04937319 MR 2 PF-04937319 MR 3

A Comparison of the Bioavailability of OZ439 When Delivered Directly to the Small Intestine, or Via the Oral Route

PHASE1

The purpose of this study is to determine the bioavailability of nanopartic...

Status

Completed

Location

Quotient Clinical

Start Date

2012-11

Trial ID

NCT01732588

Treatments Being Tested

OZ439 120mg PIB 120 mg OZ439 caplet 120mg OZ439 caplet via Enterion capsule

Effect of Food on Bioavailability of a Modified Release Formulation of Imatinib

PHASE1

This is a single center, four-treatment, four period, crossover study to ev...

Status

Completed

Location

Multiple Locations

Start Date

2006-06

Trial ID

NCT00422825

Treatments Being Tested

imatinib

Previous Next